The stock of Haemonetics Corporation (NYSE:HAE) is a huge mover today! About 279,549 shares traded hands. Haemonetics Corporation (NYSE:HAE) has risen 5.68% since March 11, 2016 and is uptrending. It has outperformed by 0.22% the S&P500.
The move comes after 5 months negative chart setup for the $1.76B company. It was reported on Oct, 14 by Barchart.com. We have $32.53 PT which if reached, will make NYSE:HAE worth $105.60 million less.
Analysts await Haemonetics Corporation (NYSE:HAE) to report earnings on November, 2. They expect $0.35 earnings per share, down 20.45% or $0.09 from last year’s $0.44 per share. HAE’s profit will be $17.80M for 24.72 P/E if the $0.35 EPS becomes a reality. After $0.25 actual earnings per share reported by Haemonetics Corporation for the previous quarter, Wall Street now forecasts 40.00% EPS growth.
Haemonetics Corporation (NYSE:HAE) Ratings Coverage
Out of 7 analysts covering Haemonetics Corporation (NYSE:HAE), 2 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 29% are positive. Haemonetics Corporation has been the topic of 11 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The rating was maintained by Benchmark on Thursday, November 5 with “Hold”. Benchmark maintained Haemonetics Corporation (NYSE:HAE) rating on Wednesday, May 11. Benchmark has “Hold” rating and $28 price target. The firm has “Outperform” rating by Barrington Research given on Tuesday, October 6. The company was upgraded on Monday, May 16 by Goldman Sachs. Sidoti downgraded the shares of HAE in a report on Monday, August 15 to “Neutral” rating. The firm has “Outperform” rating given on Tuesday, July 28 by Barrington Research. The company was downgraded on Tuesday, September 20 by CJS Securities. The company was downgraded on Monday, November 23 by Raymond James. The company was maintained on Tuesday, August 2 by Jefferies.
According to Zacks Investment Research, “Haemonetics is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collections and plasma collections. The majority of their business is outside the US.”
Insitutional Activity: The institutional sentiment decreased to 1.55 in Q2 2016. Its down 0.20, from 1.75 in 2016Q1. The ratio turned negative, as 18 funds sold all Haemonetics Corporation shares owned while 44 reduced positions. 31 funds bought stakes while 65 increased positions. They now own 50.62 million shares or 0.12% more from 50.56 million shares in 2016Q1.
Moreover, Envestnet Asset Management has 0% invested in Haemonetics Corporation (NYSE:HAE) for 25,337 shares. State Board Of Administration Of Florida Retirement Systems has invested 0% of its portfolio in Haemonetics Corporation (NYSE:HAE). Anchor Capital Advsr Ltd Liability has 905,466 shares for 0.67% of their US portfolio. Cubist Systematic Strategies Lc accumulated 22,405 shares or 0.04% of the stock. Cardinal Cap Mgmt accumulated 0.1% or 8,906 shares. Tci Wealth holds 0% or 20 shares in its portfolio. Tfs Capital Ltd holds 0.19% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 35,457 shares. Strs Ohio accumulated 35,300 shares or 0% of the stock. Blackrock Advsrs Limited Liability Co, a Delaware-based fund reported 24,381 shares. The Illinois-based Segall Bryant And Hamill Ltd Co has invested 0.05% in Haemonetics Corporation (NYSE:HAE). Teacher Retirement Systems Of Texas last reported 7,081 shares in the company. Citadel Advsrs Ltd Liability last reported 0% of its portfolio in the stock. Cipher Lp has invested 0.06% of its portfolio in Haemonetics Corporation (NYSE:HAE). Babson Cap Limited owns 13,605 shares or 0.01% of their US portfolio. Amg Trust Bank & Trust reported 15,558 shares or 0.04% of all its holdings.
Insider Transactions: Since August 4, 2016, the stock had 1 buying transaction, and 2 insider sales for $1.43 million net activity. Shares for $2.10 million were bought by Simon – Christopher on Thursday, August 4. $152,398 worth of Haemonetics Corporation (NYSE:HAE) was sold by MERRIMAN RONALD on Wednesday, August 17. Another trade for 14,685 shares valued at $519,105 was sold by FOOTE SUSAN BARTLETT.
More important recent Haemonetics Corporation (NYSE:HAE) news were published by: Prnewswire.com which released: “Haemonetics Corporation Announces Christopher Simon as President and Chief …” on May 09, 2016, also Twst.com published article titled: “Haemonetics Corporation: Haemonetics Sets Date for 2nd Quarter Fiscal 2017 …”, Prnewswire.com published: “Haemonetics Corporation Appoints Ron Gelbman as Interim CEO; CEO Brian …” on September 29, 2015. More interesting news about Haemonetics Corporation (NYSE:HAE) was released by: Prnewswire.com and their article: “Invetech, Haemonetics, and Coramed Technologies Receive 2016 Good Design Award …” with publication date: June 01, 2016.
HAE Company Profile
Haemonetics Corporation (Haemonetics), incorporated on August 29, 1985, is a healthcare company. The Firm provides various products to clients involved in the processing, handling and analysis of blood. The Company’s divisions include Japan, EMEA, North America Plasma and All Other. It provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. It provides analytical devices for measuring hemostasis, which enable healthcare providers to manage their patients’ bleeding risk. Haemonetics makes blood processing systems, and software, which tracks blood components. Haemonetics supplies systems and software, which facilitate blood transfusions and cell processing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.